Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Michael Szarek to Hyperlipoproteinemia Type II

This is a "connection" page, showing publications Michael Szarek has written about Hyperlipoproteinemia Type II.

 
Connection Strength
 
 
 
1.123
 
  1. Nicholls SJ, Nelson AJ, Ray KK, Ditmarsch M, Kling D, Hsieh A, Szarek M, Kastelein JJ, Davidson MH. Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials. Eur Heart J. 2026 Jul 07; 47(26):3404-3414.
    View in: PubMed
    Score: 0.235
  2. Nicholls SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, Ballantyne CM, Ray KK, Navar AM, Nissen SE, Goldberg AC, Brunham LR, Wuerdeman E, Neild AL, Kling D, Hsieh A, Butters J, Ference BA, Laufs U, Banach M, Mehran R, Catapano AL, Szarek M, Balinskaite V, Davidson MH. Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial. Nat Med. 2026 Mar; 32(3):1052-1060.
    View in: PubMed
    Score: 0.229
  3. Nicholls SJ, Nelson AJ, Ray KK, Ballantyne CM, Ditmarsch M, Kling D, Hsieh A, Szarek M, Kastelein JJ, Davidson MH. Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis. J Am Coll Cardiol. 2025 Oct 07; 86(14):1046-1056.
    View in: PubMed
    Score: 0.222
  4. Geba GP, Mohammadi KA, Damask A, Paulding C, Lotta LA, Hindy G, Pordy R, Manvelian G, Shapiro MD, Bittner VA, Bhatt DL, Szarek M, Schwartz GG, Steg PG, Fazio S. Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial. J Am Heart Assoc. 2025 09 02; 14(17):e041190.
    View in: PubMed
    Score: 0.221
  5. Nicholls SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, Ballantyne CM, Ray KK, Navar AM, Nissen SE, Harada-Shiba M, Curcio DL, Neild A, Kling D, Hsieh A, Butters J, Ference BA, Laufs U, Banach M, Mehran R, Catapano AL, Huo Y, Szarek M, Balinskaite V, Davidson MH. Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk. N Engl J Med. 2025 Jul 03; 393(1):51-61.
    View in: PubMed
    Score: 0.217
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)